Strong antitumor activity of bevacizumab and aflibercept in Neuroendocrine Carcinomas: In-depth preclinical study

Background Neuroendocrine carcinoma (NEC) is a rare and very aggressive tumor. It has been greatly understudied and very little is known about optimal treatment strategy for patients with this disease. The purpose of this study was to evaluate in vivo whether anti-VEGF drugs could be a therapeutic alternative for these tumors with a poor prognosis. Methods We have developed two xenograft models using either human cell line derived from lung (H460) or from colon (COLO320) NEC to assess the effect of two antiangiogenic drugs, aflibercept and bevacizumab, on tumor growth and their pathological characteristics. Additionally, tumors were subjected to immunohistochemistry staining and proteins were measurement with western blot and ELISA. Results Both aflibercept and bevacizumab showed significant antitumor activity (p
Source: Neuroendocrinology - Category: Endocrinology Source Type: research